By Dr. Alaina M. Jaster The DEA hearing to challenge the scheduling of two phenethylamine psychedelics, DOI and DOC, began on what many would deem an ordinary Tuesday morning. For one group of steadfast individuals, this morning would be the start of a seven-day hearing that could have substantial impacts on the future of drug scheduling.These individuals came from a…

Source

Previous articleThe 3-Axis Framework: A New Model for Psychedelic Integration
Next articleQ3’24 Survey: What are Psychedelics Investors Concerned About?